Kornimate/medical-research-clean huggingface dataset:
utilizing exhaled breathe condensate collection to study ion regulation in cystic fibrosis

Conditions: Cystic Fibrosis; Healthy

Summary: our aims were to determine if exhaled breath condensate (ebc) could detect differences in ion regulation between cystic fibrosis (cf) and healthy and measure the effect of the albuterol on ebc ions in these populations. we hypothesized ebc chloride and sodium would be lower in cf patients at baseline and that albuterol would decrease ebc sodium and increase ebc chloride.


Eligibility criteria:
inclusion criteria: healthy subjects: * no cardiovascular abnormalities * not overweight bmi\>25 * 18-55 years of age cf subjects: * mild to moderate cf (fev1\>40% predicted) * clinically diagnosed with positive sweat test (sweat cl-\>60mmol/l) * 10-55 years of age * clinically stable exclusion criteria: healthy subjects will be excluded if: * if unable to consent for him/herself (cognitive impairment) * have a history or evidence of cardiovascular and/or pulmonary abnormalities. * have an abnormal 12-lead ekg * have an abnormal pulmonary function test * have a history of asthma * have a history of renal disease or estimated creatinine clearance \< 55ml/min * women who are pregnant or planning to become pregnant during the study cf subjects: * if unable to consent for him/herself (cognitive impairment) * physically unable to perform exercise or breathing tests * have a history of renal disease or estimated creatinine clearance \< 55ml/min * women who are pregnant or planning to become pregnant during the study. * have an abnormal 12-lead ekg * cystic fibrosis related diabetes is uncontrolled * forced expiratory volume after 1 second (fev1) is less than 40% predicted * have a history of joint disease * have history of pulmonary exacerbation within the last two weeks * experienced pulmonary hemorrhage within 6 months resulting in greater than 50cc of blood in the sputum * not currently enrolled in any other research study

Keywords: exhaled breath condensate diffusion capacity of the lungs for carbon monoxide and nitric oxide albuterol peripheral oxygen saturation ion regulation
efficacy and safety of verteporfin added to ranibizumab in the treatment of symptomatic macular polypoidal choroidal vasculopathy

Conditions: Polypoidal Choroidal Vasculopathy

Summary: this study aims to compare the efficacy of ranibizumab and verteporfin pdt combination treatment and verteporfin pdt monotherapy vs.ranibizumab monotherapy alone in achieving complete regression of polyps in patients with symptomatic macular polypoidal choroidal vasculopathy.


Eligibility criteria:
inclusion criteria: * patients must give written informed consent before any assessment is performed. * male or female patients ≥18 yrs of age * patients willing and able to comply with all study procedures inclusion criteria for study eye: * bcva letter score between 73-24 (approximately 20/40 to 20/320 snellen equivalent) using etdrs visual acuity chart measured at 4 meters * pcv diagnosis confirmed by central reading center * greatest linear dimension (gld) of the total lesion area \< 5400 µm (\~9 macular photocoagulation study disc areas) exclusion criteria: * women of child-bearing potential who are not using one or more reliable contraception methods * pregnant or nursing (lactating) women * history of hypersensitivity or allergy to fluorescein or indocyanine green (icg), clinically significant drug allergy or known hypersensitivity to therapeutic or diagnostic protein products, or to any of the study drugs or their components * patient with history of porphyria * systemic medications known to be toxic to the lens, retina, or optic nerve * history of which might affect the interpretation of the results of the study, or renders the patient at high risk from treatment complications * use of other investigational drugs within 30 days of randomization exclusion criteria for study eye: * concomitant conditions/diseases: * presence of angioid streaks, macular fibrosis, presumed ocular histoplasmosis syndrome, pathologic myopia (-8 diopters or more) * active ocular inflammation or infection * uncontrolled glaucoma * ocular disorders that may confound interpretation of study results prior ocular treatment: * prior verteporfin pdt, external-beam radiation, laser photocoagulation, macular surgery, or transpupillary thermotherapy * prior local treatment with pegaptanib, ranibizumab, bevacizumab or other anti-angiogenic compound or any investigational treatment in both eyes or systemic use of bevacizumab within 90 days prior to randomization * history of intraocular surgery including pars plana vitrectomy and intraocular hemorrhage displacement is not allowed with the exception of uncomplicated cataract surgery that is allowed within 60 days prior to screening * ocular conditions that required chronic concomitant therapy within 90 days prior to randomization with topical, ocular, or systemically administered corticosteroids or any herbal medication known to contain steroid-like components other protocol-defined inclusion/exclusion criteria may apply

Keywords: polypoidal choroidal vasculopathy pcv age-related macular degeneration (amd) variant vision polyps indocyanine green angiography verteporfin ranibizumab photodynamic therapy
understanding sugar-sweetened beverages (ssb) and colorectal cancer (crc)

Conditions: Colorectal Neoplasms

Summary: this study will recruit and consent approximately 120 subjects in the baseline study until the follow-up study recruitment goals of 20 subjects is met. this pilot proposal to: aim 1) assess the feasibility of conducting a randomized controlled trial of isipsmarter among high-risk patients with newly detected large colorectal adenoma to reduce sugar-sweetened beverages (ssb) consumption, and aim 2) examine the investigators' central hypothesis that ssbs contribute to racial disparities in the development of side-specific colon neoplasia via differentially impacting epigenetic aging and methylation of right vs. left normal colon tissues of african-americans (aa) vs european-americans (ea). in order to do so, the investigators will first conduct a study to collect baseline information from eligible and interested participants. behavioral, lifestyle, and genetic information will be collected from participants undergoing a colonoscopy with large polypectomy removal to set up a biobank. the participants enrolled in this study will then be screened for their interest and eligibility in participating in the follow-up study, a randomized isipsmarter intervention trial. the investigators will enroll 20 patients in the follow-up study (1:1 ratio intervention vs. control; equal number of aas and eas) with newly detected/resected large colorectal adenomas to collect normal colon tissue biopsies pre- and post-isipsmarter intervention and test the investigators' hypotheses.


Eligibility criteria:
baseline study: inclusion criteria: * patients scheduled for a colonoscopy (large polyp removal) * patients 18+ exclusion criteria: * subjects who do not speak english * subjects diagnosed with inflammatory bowel disorder * subjects diagnosed with cancer (except non-melanoma skin cancer) * subjects taking blood thinners at time of colonoscopy (except 325 mg daily aspirin) follow-up study: in order to be eligible to participate in the f/up study, an individual must meet all of the criteria for the baseline study and: inclusion criteria: * regular access (\<1/week) to the internet. * drink more than recommended amount of sugar-sweetened beverages per day (assessed from participant's responses to the beverage questionnaire section (bevq-15) of the computer administered phone interview (capi), from the baseline study).
sirt-1 antagonism for endometrial receptivity

Conditions: Endometriosis; Uterine Diseases; Endometrial Diseases; Infertility Unexplained; Infertility; Female, Nonimplantation

Summary: progesterone resistance is mediated through epigenetic modification through sirt1 activation and is thought to contribute to infertility and progression of endometriosis. endometriosis is a leading cause of unexplained ivf failure secondary to inflammatory changes that induce sirt1. the current study is designed to investigate a small molecule inhibitor of sirt1, in the clinical setting of in vitro fertilization and embryo transfer. the safer trial will compare ex-527 to placebo in a randomized, double-blind trial. primary endpoints include live birth rate (lbr) and secondary outcomes include pregnancy rate (pr), miscarriage rate (mr) and implantation failure rate.

the safer trial will enroll women with unexplained failure after embryo transfer with euploid embryos. subjects must have existing euploid embryos for transfer and test positive for sirt1 testing on endometrial biopsy. to qualify, they must be 18 to 40 years of age, have a normal uterine cavity, no serious systemic diseases (diabetes, lupus, cancer, etc) and be willing to be randomized to treatment with a sirt1 inhibitor, ex-527 or placebo. the medication will be provided and administered for 5 days prior to embryo transfer, after progesterone therapy is begun. the drug will be stopped 24 hr before embryo transfer. standard protocols will be used including administration of progesterone, checking hcg 8 days after transfer, ultrasound monitoring of pregnancy and pregnancy outcomes recording, with live birth rate (lbr) being the primary outcome of interest. we expect to enroll 30 women, with 15 subjects per arm. the goal of this study is to demonstrate efficacy for a specific inhibitor of sirt1 as a primary treatment of defects in endometrial receptivity due to endometriosis.

Eligibility criteria:
inclusion criteria: * must test positive for sirt1 on mid-luteal endometrial biopsy * prior failed embryo transfer with euploid embryos * have at least one euploid embryo for transfer exclusion criteria: * systemic illness affecting kidneys or liver; chronic headache or severe migraine * endometritis, hydrosalpinges, and known adenomyosis * uterine septum, uterine fibroids, endometrial polyps

Keywords: endometriosis sirt1 progesterone resistance
sponge and eosinophil peroxidase (epo) staining

Conditions: Eosinophilic Esophagitis

Summary: are we able to use the epo staining technique using the sponge ?

epo staining on esophageal sponge samples had a strong association with peak esophageal eosinophil counts on endoscopic biopsy specimens in a small study of 26 patients using a cut-off of 1.1 absorbance units in a colorimetric assay at a wavelength of 492nm the epo stain had sensitivity and specificity of 1105 and 83% respectively for a peak eosinophil count of 15 eos/hpf on histologic endoscopic obtained biopsy specimens. the technique of epo staining is standardized and can be completed in 45 minutes time. currently, we have found esophageal sponge cytology sensitive and specific for assessment of esophageal eosinophilia. it allows disease activity assessment without endoscopy is much preferred by patients over the standard endoscopic technique of disease assessment. the process of specimen preparation in fairly tedious and interpretation takes significant experience. if epo staining on non-endoscopic esophageal sponge studies was accurate at assessing disease activity, this is a tool that could be easily performed and interpreted with a rapid turnaround time.

Eligibility criteria:
inclusion criteria: * 18 to 70 years of age * diagnosed with eosinophilic esophagitis \> than 15 eos phf and failed to respond to the ppi therapy * going through the six food elimination diet or have just completed elimination the six foods: fish, nuts, eggs, soy, wheat, and milk exclusion criteria: * clinical evidence of infectious process potentially contributing to dysphagia (e.g. candidiasis, cmv, herpes) * other cause of dysphagia identified at endoscopy (e.g. reflux esophagitis, stricture, web, ring, achalasia, esophageal neoplasm) * esophageal minimal diameter \< 13 mm on structured barium esophagram

Keywords: eoe
intensity modulated radiotherapy in recurrent t1-2 nasopharyngeal carcinoma

Conditions: Nasopharyngeal Cancer Recurrent

Summary: the hypothesis of the study is to address the efficacy and toxicity profile of aforementioned four modalities for rt1-2 npc. characters of the patients: * list item one: 168 patients, median age 48 years (range 16-75 years） proven rt1-2 npc were diagnosed * list item two: treated with four different irradiation modalities(3d-crt,imrt, bt , bt combined 3d-crt or imrt). * list item three: median time to recurrence was 30 months (range 1-180months). the median follow-up time was 28 months (range, 4-135 months).

objectives: recurrent t1-2 nasopharyngeal carcinoma (rt1-2) may be salvaged by 3d - crt（3d-conformal radiotherapy）, imrt（ intensity modulated radiotherapy）, brachytherapy (bt), bt combined 3d - crt or imrt . the aim of this study is to address the efficacy and toxicity profile of aforementioned four modalities for rt1-2 npc. methods and materials: 168 patients, median age 48 years (range 16-75 years） proven rt1-2 npc were diagnosed and treated with four different irradiation modalities(3d-crt,imrt, bt , bt combined 3d-crt or imrt) . median time to recurrence was 30 months (range 1-180months). the median follow-up time was 28 months (range, 4-135 months).

Eligibility criteria:
inclusion criteria: * recurrent t1-2 nasopharyngeal carcinoma patients exclusion criteria: * non recurrent t1-2 nasopharyngeal carcinoma patients

Keywords: superiority, re-irradiation, imrt, recurrent t1-2 npc
efficacy study of oral nicorandil on improving microvascular function in female non-obstructive coronary artery disease (cad) participants

Conditions: Non-obstructive Coronary Artery Disease

Summary: the study is a single-center, interventional, pilot study to evaluate the improvement of microvascular function by positron emission tomography (pet) after twelve-week treatment of oral nicorandil in female non-obstructive cad participants.


Eligibility criteria:
inclusion criteria: * female * participants aged 18-70 years * participants with typical stable angina but without coronary obstruction (defined as coronary occlusion less than (\<) 50%) by invasive coronary angiography or coronary computed tomography angiography (cta) in recent three months * all other long acting cardiovascular disease medicines, including but not limited to aspirin/clopidogrel, calcium channel blockers (ccb), angiotensin-converting enzyme inhibitors (acei)/angiotensin ii receptor blockers (arb), beta-blockers, statins, ivabradine, trimetazidine, et al, should be stable taken for at least two weeks before screening period * for participants who met these four criteria above, mfr will be tested by stress pet. participants whose mfr \<3.0 could be included in the study exclusion criteria: * severe or uncontrolled hypertension (resting systolic blood pressure \[sbp\] \>=160 millimeter of mercury (mmhg), or resting diastolic blood pressure \[dbp\] \>=100mmhg at screening period) * participants with shock (including cardiogenic shock), or hypovolemia * severe hypotension (resting sbp\<90mmhg，or resting dbp\<60mmhg) * significant valvular heart disease, congenital heart disease or cardiomyopathy * congestive heart failure(new york heart association \[nyha\] iii-iv), echocardiographic ejection fraction\<45% * acute pulmonary edema; * hepatic or renal dysfunction, defined as: * serum alanine aminotransferase (alt) \> triple of the normal value upper limit; * serum aspartate aminotransferase (ast) \> triple of the normal value upper limit * serum creatinine \> twice of the normal value upper limit * glaucoma * active peptic ulcer or active skin ulcer * taking glyburide, phosphodiesterase type 5 (pde-5) inhibitor, soluble guanylate cyclase stimulator(s) * known to be hypersensitivity to nicorandil, nitrates, niacin, or any of the excipient * with contraindication to complete stress pet test * no legal ability and legal ability is limited * participants unlikely to cooperate in the study or with inability or unwillingness to give informed consent * child-bearing period women without effective contraceptive measures, pregnancy and lactation * participation in another clinical trial within the past 30 days * other significant disease that in the investigator's opinion would exclude the participant from the trial

Keywords: non-obstructive coronary artery disease nicorandil
objective functional outcome measures in orthopedic surgery using advanced tracking technologies

Conditions: Orthopedic Disorders

Summary: the proposed project will address the measurement and ramifications of out-of-home mobility problems in various orthopedic disorders in an innovative way, using advanced tracking technologies.


Eligibility criteria:
inclusion criteria: * unwillingness to sign informed consent. exclusion criteria: * pregnancy.

Keywords: orthopedic surgical procedures
efficacy and safety of kaletra monotheraphy compared to kaletra based triple therapy to treat hiv in antiretroviral naїve patients

Conditions: HIV Infection

Summary: the purpose of this pilot study is to obtain a preliminary assessment of the antiviral activity and tolerability of kaletra single agent therapy as initial treatment for hiv infection, relative to a kaletra three drug standard of care reference arm


Eligibility criteria:
inclusion criteria: * antiretroviral naïve * hiv rna \<100,000 copies/ml * cd4 cell count \>100 cells/ml at screening * with karnofsky score \> 70 * if female, * non-pregnant and * not breastfeeding * no aids opportunistic infection within 30 days of screening exclusion criteria: * subject with an hiv primo-infection status * recent history of drug and/or alcohol abuse * history of psychiatric illness * if presence of the following mutations : * in the protease : one among 32,47,48,50,82,84,90 * or more than 3 mutations from the other points of the lpv mutation score:10,20,24,46,53,54,63,71 * in the reverse transcriptase : 215 or 184. * if abnormal laboratory results such as : * hb\<8 g/dl * absolute neutrophil count\<750 cells/µl * platelet count\<50 000/ml

Keywords: hiv infection kaletra lopinavir ritonavir treatment naive
the effect of music on weight lifters

Conditions: Exercise Overtraining

Summary: the effects of listening to music on anaerobic power in elite weightlifting athletes will be examined.

the aim of the study was to investigate the effects of music listening on anaerobic power in elite weightlifting athletes.there is no study in the literature examining the relationship between music listening and anaerobic power in elite weightlifting athletes. since our study will be the first to investigate the subject, we foresee that it is scientifically important and will shed light on future studies. in addition, national or international publications are planned after the study is completed.

Eligibility criteria:
inclusion criteria: * being an elite weightlifter, volunteering for research exclusion criteria: * if you have any disability that may prevent the test, hearing problems
radiofrequency for chronic post-mastectomy pain: is it better to target intercostal nerves or corresponding dorsal root ganglia?

Conditions: Post-Mastectomy Chronic Pain Syndrome

Summary: neuropathic pain can occur following any surgical procedure on the breast ..

chronic pain affects the daily lives of post-surgical breast cancer patients. many of these patients were undertreated for pain and generally obtained poor pain relief.treated patients with chronic thoracic segmental pain including patients with post-mastectomy pain syndrome by radiofrequency for dorsal root ganglion reported longterm pain relief.

Eligibility criteria:
inclusion criteria: * patients with chronic post-mastectomy pain for at least 3 months post operatively. * patients with visual analogue scale for pain score \> 4 * patients treated with more than one line of anti-neuropathic drugs. exclusion criteria: * patient refusal. * coagulopathy. * chest and back deformity. * infection at the introduction site of the needle .
levetiracetam for neuroprotection against corticosteroid-induced hippocampal dysfunction: a proof of concept study

Conditions: Memory Loss Associated With Corticosteroid Use; Manic State Associated With Corticosteroid Use

Summary: the purpose of this research is to determine whether the memory impairment and manic symptoms (feelings of agitation, overexcitement or hyperactivity) typically seen in those on corticosteroid therapy is decreased with a seizure medication called levetiracetam compared to placebo (an inactive substance). since increased levels of cortisol (the body's natural corticosteroid) in the body are frequently associated with memory impairment interventions that may prevent or reverse this are of great importance. it is hypothesized that patients who are scheduled to receive prescription corticosteroid therapy who are given levetiracetam pretreatment will show lesser memory impairment and manic symptoms than those receiving placebo.


Eligibility criteria:
inclusion criteria: * age 18-65 years * scheduled to receive a corticosteroid "burst" of at least 10 mg of prednisone equivalents and for at least 5 days duration * english- or spanish-speaking exclusion criteria: * history of allergic reaction or other contraindication to levetiracetam therapy * other unstable medical conditions (e.g. recent myocardial infarction, renal failure, diabetes with poor glycemic control) * pregnant or nursing women * history of mental retardation, dementia or other severe cognitive disorders
psychometric properties of four step tests and effects of step training in reducing falls on older adults with dementia

Conditions: Dementia

Summary: abstract: objectives: (i) to investigate the test-retest and inter-rater reliability, construct and known-group validity of four independent step tests in older adults with mild to moderate dementia (phase 1); and (ii) the feasibility and effects of a 12-week step training on the step performance, physical and functional outcomes in this population (phase 2). design and subjects: older adults who have mild to moderate dementia, and able to walk independently without walking aids, with stick or quadripod will be recruited to participate in this study. participants will perform four step tests, including four square step test (fsst), choice stepping reaction time test (csrtt), maximum step length test (mslt) and alternate step test (ast) on three separate testing occasions conducted by two independent raters at the baseline (phase 1). the participants will then join either an intervention or control group. those in the intervention group will receive a 12-week step training, while the control group will receive usual care. the stepping performance using the step tests validated in phase 1, cognitive and functional outcomes and prospective falls will be compared between the intervention and control groups at 12 and 24 weeks (phase 2). interventions: the step training consists of two 30-minute training sessions per week. the participants will receive an individualized, progressive training that is tailored to their stepping ability and cognitive function. main outcome measures: stepping performance using the four step tests, 2-minute walk test, 10-meter walk test, 30-second sit to stand test, berg balance scale, montreal cognitive assessment and prospective falls at 12 and 24 weeks. expected results: (i) the four step tests are reliable in older adults with mild to moderate dementia, and the findings of the step tests are moderately associated with the functional outcomes, and (ii) the participants in the intervention group will have better stepping performance, better functional outcomes and fewer falls compared with the control group at 12 weeks, and the effects will sustain at 24 weeks.


Eligibility criteria:
inclusion criteria: * 65 years or above * able to walk independently without walking aid, with stick or quadripod * clinical diagnosis of dementia exclusion criteria: * unstable cardiac or pulmonary conditions * acute musculoskeletal or severe neurological conditions affecting stepping performances * severe hearing or visual impairment limiting communication * severe cognitive impairment * recent hospitalization in the past 30 days